Kadcyla FDA Approval History
FDA Approved: Yes (First approved February 22, 2013)
Brand name: Kadcyla
Generic name: ado-trastuzumab emtansine
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Breast Cancer
Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated for the treatment of patients with HER2-positive, metastatic breast cancer.
Development timeline for Kadcyla
| Date | Article |
|---|---|
| May 3, 2019 | Approval FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer |
| Feb 22, 2013 | Approval FDA Approves Kadcyla for Late-Stage Breast Cancer |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.